omecamtiv mecarbil Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Omecamtiv mecarbil (INN), previously referred to as CK-1827452, is a cardiac-specific myosin activator. It is an experimental drug being studied for a potential role in the treatment of left ventricular systolic heart failure.   Wikipedia

Chemistry

  • SMILES: COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1
  • InChIKey: RFUBTTPMWSKEIW-UHFFFAOYSA-N
  • Mol. Mass: 401.44
  • ALogP: 3.06
  • ChEMBL Molecule:
    omecamtiv mecarbil  
More Chemistry

Pharmacology

Alternative names

amg 423 | amg-423 | ck 1827452 | ck-1827452 | omecamtiv mecarbil

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Angina Pectoris (Phase 2)

Healthy Volunteers (Phase 1)

Heart (Phase 2)

Heart Failure (Phase 3)

Heart Failure, Systolic (Phase 3)

Hypertrophy, Left Ventricular (Phase 2)

Myocardial Ischemia (Phase 2)

Pharmacokinetics (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue